Similarly, phase II trials investigating vibostolimab, another anti-TIGIT mAb, in combination with pembrolizumab (KeyVibe-003 in NSCLC and KeyVibe-007 in SCLC) also failed to demonstrate significant clinical benefit [60]. The gene discussed is TIGIT; the disease is non-small cell lung carcinoma.